CD19 Monoclonal Antibody (HIB19), Brilliant Violet™ 711, eBioscience™, Invitrogen™

Description

• The HIB19 mAb reacts with human CD19, a 95 kDa transmembrane glycoprotein
• CD19 is expressed by B cells during all stages of development excluding the terminally differentiated plasma cells
• Follicular dendritic cells also express CD19
• Together CD21, CD81, Leu13, MHC class II, and CD19 form a multimolecular complex that associates with BCR
• Signaling through CD19 induces tyrosine phosphorylation, calcium flux and proliferation of B cells
• The SJ25C1 antibody and the HIB19 mAb recognize overlapping epitopes
• Applications Reported: This HIB19 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This HIB19 antibody has been pre-diluted and tested by flow cytometric analysis of normal human peripheral blood cells
• BV 711 is a tandem dye that emits at 713nm and is intended for use on cytometers equipped with a violet (405nm) laser
• When using two or more Super Bright, BV, BUV, or other polymer dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Complete Staining Buffer (SB-4401-42) or Brilliant Stain Buffer (00-4409-75) to minimize any non-specific polymer interactions
• Our internal testing suggests that BV 711 is not compatible with methanol-based fixation
• Excitation: 407nm; Emission: 713nm; Laser: Violet Laser
• BV is a trademark or registered trademark of Becton, Dickinson and Company or its affiliates, and is used under license
• Powered by Sirigen
• CD19 is a member of the immunoglobulin superfamily and has two Ig like domains
• The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lambda light chains
• CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage
• Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen
• The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation, and is expressed in all B cell precursor leukemias
• Lymphocytes proliferate and differentiate in response to various concentrations of different antigens
• The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors
• CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation
• Besides being a signal-amplifying coreceptor for the B cell receptor (BCR), CD19 can also signal independently of BCR co-ligation and is a central regulatory component upon which multiple signaling pathways converge
• Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.